Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons

Drugs and Aging

Volumn 21, Issue 1, 2004, Pages 19-41

  Nikolaus, Thorsten ^a,b   Zeyfang, Andrej ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Bethesda Geriatrische Klinik Ulm gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CELECOXIB; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DICLOFENAC; DIPYRONE; FENTANYL; HYDROMORPHONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MORPHINE; NALOXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PIROXICAM; ROFECOXIB; TILIDINE; TRAMADOL; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; AGITATION; AGRANULOCYTOSIS; ANALGESIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; BEHAVIOR THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; FRAGILITY FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLAUCOMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; LIVER TOXICITY; MYOCLONUS; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOTHERAPY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUSTAINED RELEASE PREPARATION; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; TREMOR; URINE RETENTION; URTICARIA; WORLD HEALTH ORGANIZATION;

AGED; ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX;

EID: 0442291760     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421010-00003     Document Type: Review

References (279)

1. Helme RD, Gibson SJ. Pain in older people. In: Crombie IK, Croft PR, Linton SJ, et al., editors. Epidemiology of pain. Seattle: IASP Press, 1996: 103-12
2. Nikolaus T. Assessment of chronic pain in the elderly [in German]. Ther Umsch 1997; 54: 340-4
3. Gagliese L, Melzack R. Age differences in the quality of chronic pain: a preliminary study. Pain Res Manag 1997; 2: 157-62
4. Crook J, Rideout E, Browne G. The prevalence of pain complaints in a general population. Pain 1984; 18: 299-314
5. Brattberg G, Parker MG, Thorslund M. A longitudinal study of pain: reported pain from middle age to old age. Clin J Pain 1997; 13: 144-9
6. Badley EM, Tennat A. Changing profile of joint disorders with age: findings from a postal survey of the population of Calderdale, West Yorkshire, United Kingdom. Ann Rheum Dis 1992; 51: 366-71
7. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28
8. Stembach RA. Survey of pain in the United States: the Nuprin pain report. Clin J Pain 1986; 2: 49-53
9. Andersson HI, Ejilertsson G, Leden I, et al. Chronic pain in a geographically defined population: studies of differences in age, gender, social class and pain localization. Clin J Pain 1993; 9: 174-82
10. Cooner E, Amorosi S. The study of pain in older Americans. New York: Louis Harris and Associates, 1997
11. Roy R, Thomas M. A survey of chronic pain in an elderly population. Can Fam Physician 1986; 32: 513-6
12. Roy R, Thomas MR. Elderly persons with and without pain: a comparative study. Clin J Pain 1987; 3: 102-6
13. Brattberg G, Parker MG, Thorslund M. The prevalence of pain among the oldest old in Sweden. Pain 1996; 67: 29-34
14. Brochet B, Michel P, Barberger-Gateau P, et al. Population-based study of pain in elderly people: a descriptive survey. Age Ageing 1998; 27: 279-84
15. Ferrell BA, Ferrell BR, Osterweil D. Pain in the nursing home. J Am Geriatr Soc 1990; 38: 409-14
16. Scudds RJ, Robertson JM. Empirical evidence of the association between the presence of musculoskeletal pain and physical disability in community-dwelling senior citizens. Pain 1998; 75: 229-35
17. Casten RJ, Parmelee PA, Kleban MH, et al. The relationships among anxiety, depression, and pain in a geriatric institutionalized sample. Pain 1995; 61: 271-6
18. Parmelee PA, Katz IR, Lawton MP. The relation of pain to depression among instituionalized aged. J Gerontol 1991; 46: P15-21
19. Williamson GM, Schulz R. Pain, activity restriction, and symptoms of depression among community-residing adults. J Gerontol 1992; 47: 367-72
20. Magni G, Caldieron C, Rigatti-Luchini S, et al. Chronic musculoskeletal pain and depressive symptoms in the general population: an analysis of the 1st National Health and Nutrition Examination Survey data. Pain 1990; 43: 299-307
21. Lichtenstein MJ, Dhanda R, Cornell JE, et al. Disaggregating pain and its effect on physical functional limitations. J Gerontol 1998; 53: M361-71
22. Helme RD, Katz B, Gibson SJ, et al. Multidisciplinary pain clinics for older people: do they have a role? Clin Geriatr Med 1996; 12: 563-82
23. Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: a prevalence study. Pain 2001; 89: 127-34
24. Mantyselka P, Kumpusalo E, Ahonen R, et al. Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain 2001; 89: 175-80
25. Lavsky-Shulan M, Wallace RB, Kohout FJ, et al. Prevalence and functional correlates of low back pain in the elderly: the Iowa 65+ Rural Health Study. J Am Geriatr Soc 1985; 33: 23-8
26. Sengstaken EA, King SA. The problem of pain and its detection among geriatric nursing home residents. J Am Geriatr Soc 1994; 41: 541-4
27. Ferrell BA, Ferrell BR, Rivera I. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995; 10: 591-8
28. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group (Systematic Assessment of Geriatric Drug Use via Epidemiology). JAMA 1998; 279: 1877-82
29. Weiner D, Peterson B, Ladd K, et al. Pain in nursing home residents: an exploration of prevalence, staff perspectives and practical aspects of measurement. Clin J Pain 1999; 15: 92-101
30. Weiner D, Peterson B, Logue P, et al. Predictors of pain selfreport in nursing home residents. Aging Clin Exp Res 1998; 10: 411-20
31. Feldt KS, Ryden MB, Miles S. Treatment of pain in cognitively impaired compared with cognitively intact older patients with hip-fracture. J Am Geriatr Soc 1998; 46: 1079-85
32. Farrell MJ, Katz B, Helme RD. The impact of dementia on the pain experience. Pain 1996; 67: 612-9
33. Duggleby W, Lander J. Cognitive status and postoperative pain: older adults. J Pain Symptom Manage 1994; 9: 19-27
34. Marzinski LR. The tragedy of dementia: clinically assessing pain in the confused, nonverbal elderly. J Gerontol Nurs 1991; 17: 25-8
35. Avorn J, Gurwitz JH. Drug use in the nursing home. Ann Intern Med 1995; 123: 195-204
36. Cutler RB, Fishbain DA, Rosomoff RS, et al. Outcomes in treatment of pain in geriatric and younger age groups. Arch Phys Med Rehabil 1994; 75: 457-64
37. Gibson SJ, Helme RD. Age-related differences in pain perception and report. Clin Geriatr Med 2001; 17: 433-56
38. Chakour MC, Gibson SJ, Bradbeer M, et al. The effect of age on A-delta and C-fibre thermal pain perception. Pain 1996; 64: 143-52
39. Sorkin BA, Rudy TE, Hanlon RB, et al. Chronic pain in old and young patients: differences appear less important than similarities. J Gerontol 1990; 45: P64-8
40. Gibson SJ, Voukelatos X, Ames D, et al. An examination of pain perception and cerebral event-related potentials following carbon dioxide laser stimulation in patients with Alzheimer's disease and age-matched control volunteers. Pain Res Manag 2001; 6: 126-32
41. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons: American Geriatrics Society. J Am Geriatr Soc 2002; 50: S205-24
42. Feldt KS, Warne MA, Ryden MB. Examining pain in aggressive cognitively impaired older adults. J Gerontol Nurs 1998; 24: 14-22
43. Grossberg GT, Sherman LK, Fine PG. Pain and behavioural disturbancies in the cognitively impaired older adult: assessment and treatment issues. Ann Long Term Care 2000; 8: 22-4
44. Miller J, Neelon V, Dalton J, et al. The assessment of discomfort in elderly confused patients: a preliminary study. J Neurosci Nurs 1996; 28: 175-82
45. Weiner D, Hanlon J. Pain in nursing home residents: management strategies. Drugs Aging 2001; 18: 13-29
46. Won A, Lapane K, Gambassi G, et al. Correlates and management of nonmalignant pain in the nursing home. J Am Geriatr Soc 1999; 47: 936-42
47. Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med 1995; 123: 681-7
48. AGS Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons: American Geriatrics Society. J Am Geriatr Soc 1998; 46: 635-51
49. Melzack R, Katz J. The McGill Pain Questionnaire: appraisal and current status. In: Turk DC, Melzack R, editors. Handbook of pain assessment. New York: Guilford Press, 1992: 152-68
50. Briggs M, Closs JS. A descriptive study of the use of visual analogue scales and verbal rating scales for the assessment of postoperative pain in orthopaedic patients. J Pain Symptom Manage 1999; 18: 438-46
51. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38
52. Gloth FM, Scheve AA, Stober BS, et al. The functional pain scale: reliability, validity and responsiveness in an elderly population. J Am Med Dir Assoc 2001; 2: 110-4
53. Scherder EJ, Bouma A. Visual analogue scales for pain assessment in Alzheimer's disease. Gerontology 2000; 46: 47-53
54. Wynne CF, Ling SM, Remsburg R. Comparison of pain assessment intruments in cognitively intact and cognitively impaired nursing home residents. Geriatr Nurs 2000; 21: 20-3
55. Huskisson EC. Measurement of pain. Lancet 1974; II: 1127-31
56. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986; 27: 117-26
57. Herr KA, Mobily PR. Comparison of selected pain assessment tools for use with the elderly. Appl Nurs Res 1993; 6: 39-46
58. Herr KA, Mobily PR, Kohout FJ, et al. Evaluation of the faces pain scale for the use with the elderly. Clin J Pain 1998; 14: 29-38
59. Roland M, Morris R. A study of the natural history of back pain: development of a reliable and sensitive measure of disability in low-back pain. Spine 1983; 8: 141-4
60. Chibnall JT, Tait RC. Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales. Pain 2001; 92: 173-86
61. Weiner D, Pieper C, Mc Connell E, et al. Pain measurement in elders with chronic low back pain: traditional and alternative approaches. Pain 1996; 67: 461-7
62. Melzack R, The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-7
63. Herr KA, Mobily PR. Complexities of pain assessment in the elderly: clinical considerations, J Gerontol Nurs 1991; 17: 12-9
64. Cook AJ. Cognitive-behavioural pain management for elderly nursing home residents. J Gerontol 1998; 53: P51-9
65. Johnson M, Ashton CH, Thompson JW. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS): implications for clinical use of TENS. Pain 1991; 44: 221-9
66. Kost RG, Strauss SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32-42
67. Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back in older adults. J Am Geriatr Soc 2003; 51: 599-608
68. American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. J Am Geriatr Soc 2001; 49: 808-23
69. Ettinger WH, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997; 277: 25-31
70. Kanis JA. Osteoporis. Oxford: Blackwell Science Ltd, 1994
71. Ferrell BA, Josepheson KR, Pollan AM, et al. A randomized trial of walking versus physical methods for chronic pain management. Aging Clin Exp Res 1997; 9: 99-105
72. Ferrell BR. Patient education and non-drug intervention. In: Ferrell BR, Ferrell BA, editors. Pain in the elderly. Seattle: IASP Press, 1996: 35-44
73. Keefe FJ, Caldwell DS, Queen KT, et al. Pain coping strategies in osteoarthritis patients. J Consult Clin Psychol 1987; 55: 208-12
74. Keefe FJ, Williams DA. A comparison of coping strategies in chronic pain patients in different age groups. J Gerontol 1990; 45: P161-5
75. Wright D, Barrow S, Fisher AD, et al. Influence of physical, psychological and behavioral factors on consultations for back pain. Br J Rheumatol 1995; 34: 156-61
76. Ferrell BR, Rhiner M, Ferrell BA. Development and implementation of a pain education program. Cancer 1993; 72: 3426-32
77. Hirano PC, Laurent DD, Lorig K. Arthritis patient education studies, 1987-1991: a review of the literature. Patient Educ Couns 1994; 24: 9-54
78. Weinberger M, Tierney WM, Booher P, et al. Can the provision of information to patients with osteoarthitis improve functional status?: a randomized controlled trial. Arthritis Rheum 1989; 32: 1577-83
79. Taal E, Rasker JJ, Wiegman O. Group education for rheumotoid arthritis patients. Semin Arthritis Rheum 1997; 26: 805-16
80. Mazzuca SA, Brandt KD, Katz BP, et al. Effects of self-care education on health status of inner-city patients with osteoarthritis. Arthritis Rheum 1997; 40: 1466-74
81. LeFort SM, Gray-Donald K, Rowat KM, et al. Randomized controlled trial of community-based psychoeducation program for the self-management of chronic pain. Pain 1998; 74: 297-306
82. Rakel B, Barr JO. Physical modalities in chronic pain management. Nurs Clin North Am 2003; 38: 477-94
83. Abbot NC, Harkness EF, Stevinson C, et al. Spiritual healing as a therapy for chronic pain: a randomized, clinical trial. Pain 2001; 91: 79-89
84. Braverman DL, Ericken JJ, Shah RV, et al. Interventions in chronic pain management: complementary techniques. Arch Phys Med Rehabil 2003; 84: S45-9
85. World Health Organisation. Cancer pain relief with a guide to opioid availability. 2nd ed. Geneva: WHO, 1996
86. Portenoy RK. Opiod therapy for chronic non-malignant pain: current status. In: Fields HI, Libeskind JC, editors. Progress in pain research and management, Seattle: IASP Press, 1994: 247-88
87. Porter J, Jick H. Addiction rare in patients treated with narcotics [letter]. N Engl J Med 1980; 302: 123
88. Forman WB. Opioid analgesic drugs in the elderly. Clin Geriatr Med 1996; 12: 489-500
89. Fine PG. Opioid analgesic drugs in older people. Clin Geriatr Med 2001; 17: 479-87
90. Max MB, Payne R, Edwards WT, et al. Principles of analgesic drug use in the treatment of acute pain and cancer pain. 4th ed. Glenville II: American Pain Society, 1999
91. Nikolaus T. Chronic pain must not simply be accepted: which analgesic for which patient? [in German]. MMW Fortschr Med 2000; 142: 968-72
92. World Health Organisation. Cancer pain relief and palliative care: report of a WHO expert committee. Geneva, Switzerland: WHO, 1990
93. Gordon DB. Pain management in the elderly. J Perianaesth Nurs 1999; 14 (6): 367-72
94. Phillips AC, Polisson RP, Simon LS. NSAIDs and the elderly: toxicity and economic implications. Drugs Aging 1997; 10 (2): 119-30
95. Murray MD, Brater DC. Nonsteroidal anti-inflammatory drugs. Clin Geriatr Med 1990; 6: 365-441
96. Bell GM, Schnitzer TJ. COX-2 Inhibitors and other nosteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clin Geriatr Med 2001; 17 (3): 489-502
97. Fu JY, Masferrer JL, Seibert K. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40
98. Crofford L, Lipsky P, Brooks P, et al. Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum 2000; 43 (1): 4-13
99. Whelton A, Fort JG, Puma JA, et al. Cyclooxigenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8 (2): 85-95
100. Brune K, Hinz B, Zeilhofer HU. Rational basis for the use of non-steroidal antiinflammatory drugs (and selective COX-2 inhibitors) [in German, abstract in English]. Akt Rheumatol 1999; 24: 102-8
101. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
102. Thomas J, Straus WL, Bloom BS. Over-the-counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002; 97 (9): 2159-61
103. Monti DA, Kunkel EJS. Management of chronic pain among elderly patients. Psychiatr Serv 1998; 49 (12): 1537-9
104. Recognition of chronic pain in elderly patients [editorial]. Trauma 2001; 43 (3): 1-3, 6
105. Rainsford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 1981; 250: 180-94
106. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 115: 787-96
107. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996 Jun; 312: 1563-6
108. Shimp LA. Safety issues in the pharmacologic management of chronic pain in the elderly. Pharmacotherapy 1998; 18 (6): 1313-22
109. AGS Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons. Geriatrics 1998 Oct; 53 Suppl. 3: S8-S24
110. Brune K, Beyer A, Schäfer M. Schmerz [in german]. Berlin: Springer-Verlag, 2001
111. Lapane KL, Spooner JJ, Mucha L, et al. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001; 49: 577-84
112. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
113. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998 Dec; 51 (12): 1357-65
114. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-9
115. Workman BS. Management of chronic pain in older people. Aust J Hosp Pharm 1998; 28 (5): 361-7
116. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34
117. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprozole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 Dec; 347: 2104-10
118. Meyer UA. Metabolic interaction of the proton pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 Suppl. 1: S21-5
119. Chawla PS, Kochar MS. Effect of pain and nonsteroidal analgesics on blood pressure. WMJ 1999 Sep-Oct; 98 (6): 22-25
120. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A metaanalysis. Ann Intern Med 1994; 121: 289-300
121. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of ontensive blood-pressure lowering and low-dose aspirin in patients with hypertension: pricipal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351 (9118): 1755-62
122. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
123. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Mar; 151: 488-96
124. Epstein M. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens 2002 Sep; 20 Suppl. 6: S17-23
125. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-9
126. Fored MC, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin and chronic renal failure. N Engl J Med 2001; 345: 1801-8
127. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002 Dec; 32 (3 Suppl. 1): 33-42
128. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 1-9
129. Rowbotham MC. Topical analgesic agents. In: Fields HL, Liebeskind JC, editors. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle (WA): IASP Press, 1994: 211-27
130. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995 Jan-Feb; 49 (1): 33-5
131. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions: a review of the literature. Drugs 1998; 56: 783-99
132. Grace D, Rogers J, Skeith K, et al. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26 (12): 2659-63
133. Airaksinen L, Venalainen J, Pietilainen T, et al. Ketoprofen 2.5% gel versus placebo gel in the treatment of acute soft tissue injuries. J Clin Pharm Ther Toxicol 1993; 31: 561-3
134. Hawkey CJ. COX-2 Inhibitors. Lancet 1999; 353: 307-14
135. Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res 2002; 22 (1): 1-6
136. Willburger RE, Wittenberg RH, Schmidt K, et al. Antiinflammatory effect of tepoxalin. Acta Orthop Scand 1998; 69 (3): 295-300
137. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20
138. Celebrex® [prescribing information]. Karlsruhe [in German]: Pfizer, 2002
139. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000 Sep; 284 (10): 1247-55
140. Epstein M. Cardiovascular and renal effects of COX-2 specific inhibitors: recent insights and evolving clinical implications. Am J Ther 2001 Mar-Apr; 8 (2): 81-3
141. Arzneimittelkommission der deutschen Ärzteschaft: Zur Sicherheit von COX-2-Inhibitoren Deutsches Ärzteblatt 99, Ausgabe 22 vom 31.05.2002, Seite A-1535 / B-1308 / C-1223
142. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and reheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 Sep; 325: 619-23
143. Depré M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specifity, and tolerabilityof supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-74
144. Truitt KE, Sperling RS, Ettinger WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging Clin Exp Res 2001; 13: 112-21
145. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000 May; 43 (5): 978-87
146. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002 Sep; 325: 624-7
147. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19 Suppl. 25: S31-6
148. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002 Oct; 360: 1071-3
149. White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929-34
150. Brater CD, Harris C, Redfern JS. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21: 1-15
151. Zhao SZ, Reynolds MW, Lefkowith JB, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib based on the World Health Organisation/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478-91
152. Catella-Lawson F, McAdam B, Morrison BW. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41
153. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1-9
154. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61 (8): 1133-41
155. Daniels SE, Grossmann EH, Kuss ME, et al. A double-blind, randomised comparison of intramusculary and intravenuosly administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001; 23 (7): 1018-31
156. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors. J Allergy Clin Immunol 2002; 109 (2): 370-4
157. Breidung R. Schmerztherapie. Stuttgart: Aesopus-Verlag. 2002
158. Bradly JD, Brandt KD, Katz BP, et al. Comparison of an anti-inflammatory dose of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis in the knee. N Engl J Med 1991; 325: 87-91
159. Courtney P, Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 2002; 61 (9): 767-73
160. Rumore MM, Blaiklock RG. Influence of age-dependent pharmacokinetics and metabolism on acetaminophen hepatotoxicity. J Pharm Sci 1992; 81: 203-7
161. Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001; 49: 188-99
162. Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19 (6): 419-24
163. Whitcomb DC. Block GD. Association of acetaminophen hepatotoxicity with fasting and alcohol use. JAMA 1994; 272: 1845-50
164. Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7 (2): 123-34
165. Moynihan R. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year. BMJ 2002; 325 (7366): 678
166. Van den Bemt PMLA, Geven LM, Kuitert NA. The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci 2002; 24 (5): 201-4
167. De Craen AJM, Di Giulio G, Lampe-Schoenmaeckers AJEM, et al. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996; 313: 325-9
168. Kjaersgaard-Andersen P, Nafei A, Skov O. Codeine plus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain 1990; 43 (3): 309-18
169. Pincus T, Swearingen C, Cummins P, et al. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomittant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27 (4): 1020-7
170. Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: CIOMS Working Group IV, 1998
171. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002 Jul; 58 (4): 265-74
172. International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749-57
173. Martinez Martin P, Raffaelli Jr E, Titus F, et al. Efficacy and safety of metamizol vs acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalgia 2001; 21 (5): 604-10
174. Zylber-Katz E, Granit L, Stessmann J, et al. Effect on age on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol 1989; 36: 513-6
175. Novalgin® [prescribing information]. Frankfurt/Main: Aventis Pharma, 2000
176. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996; 15 (1): 8-29
177. Mullican WS, Lacy JR, Tramadol/acetaminophen combination tablets and codein/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23: 1429-45
178. Raffa RB. Pharmacology of oral combination analgesics; rational therapy for pain. J Clin Pharmacol Ther 2001; 26: 257-64
179. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7-22
180. Schnitzer TJ, Gray WI, Paster RZ, et al. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000; 27: 772-8
181. Fleischmann RM, Caldwell JR, Roth SH, et al. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001; 62: 113-28
182. Harati Y, Gooch C, Swenson M, et al. Maintenance of long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000; 14: 65-70
183. Moulin D. Tramadol for the treatment of the pain in diabetic neuropathy [letter]. Neurology 1999; 52: 1301
184. Tramal® [prescribing information]. Aachen: Grünenthal GmbH. 2003
185. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862-9
186. Parris W, Johnson B, Croghan M, et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 1998; 16: 205-11
187. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37-45
188. Ytterberg S, Mahowald M, Woods S. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998; 41: 1603-11
189. Peloso P, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27: 764-71
190. Brennscheidt U, Seiler KU, Thomann P. Pharmacokinetics of nortilidine and naloxone after administration of tilidine/nalox-one solution or tilidine/naloxone sustained release tablets. Arzneimittel Forschung 2000; 50: 1015-22
191. Hajda JP, Jahnchen E, Oie S, et al. Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine. J Clin Pharmacol 2002; 42: 1257-61
192. Wehrmann T, Rausch D, Seiler KU, et al. Tilidine does not affect human sphincter of Oddi motility: a randomized, controlled study. Aliment Pharmacol Ther 1997; 11: 987-92
193. Regenthal R, Kruger M, Richter M, et al. Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. Hum Exp Toxicol 1998; 17: 593-7
194. Wörz R, Wörz E. Long-term treatment of chronic pain with tilidine-naloxone: an analysis of 50 patients with chronic pain conditions of non-malignant origin [in German]. Fortschr Med 1995; 113: 388-92
195. Seiler KU, Jahnchen E, Trenk D, et al. Pharmacokinetics of tilidine in terminal renal failure. J Clin Pharmacol 2001; 41: 79-84
196. Bellville JW, Forrest WH, Miller E, et al. Influence of age on pain relief from analgesics: a study of postoperative patients. JAMA 1971; 271: 1835-941
197. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159-65
198. Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther 1980; 28: 823-6
199. Weinberg DS, Inturrisu CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 43: 335-42
200. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37: 17-40
201. Stanski DR, Greenblatt DJ, Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 1978; 24: 52-9
202. Kaiko RF, Wallenstein SL, Rogers AG, et al. Narcotics in the elderly. Med Clin North Am 1982; 66: 1079-89
203. Owen JA, Sitar DS, Berger L, et al. Age-related morphine kinetics. Clin Pharmacol Ther 1983; 34: 364-8
204. Baillie SP, Bateman DN, Coates PE, et al. Age and the pharmacokinetics of morphine. Age Ageing 1989; 18: 258-62
205. Chan K, Kendall MJ, Mitchard J, et al. The effect of aging on plasma pethidine concentration. Br J Clin Pharmacol 1975; 2: 297-302
206. Holmberg L, Odar-cederlof I, Boreus LO, et al. Comparative disposition of pethidine and norpethidine in the old and young patients. Eur J Clin Pharmacol 1982; 22: 175-9
207. Herman RJ, McAllister CD, Branch RA, et al. Effects of age on meperidine disposition. Clin Pharmacol Ther 1985; 37: 19-24
208. Odar-Cederlof I, Boreus LO, Bondesson U, et al. Comparison of renal
209. Hanlon JT, O'Brien JG. The pharmacological management of the elderly patient with terminal cancer pain. J Ger Drug Ther 1989; 3: 5-30
210. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 1154-8
211. Payne R, Mathias S, Pasta D, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588-93
212. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life: The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254-61
213. Fine PG. Opioid analgesic drugs in older people. Clin Geriatr Med 2001; 17: 479-87
214. Holdsworth MT, Forman WB, Killilea TA, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994; 40: 32-7
215. Nugent M, Davis C, Brooks D, et al. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage 2001; 21: 385-91
216. Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998; 16: 102-11
217. Thompson JP, Bower S, Liddle AM, et al. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 1998; 81: 152-4
218. Dellemijn PL, van Duijn H, Vanneste J. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998; 16: 220-9
219. Lindena G, Arnau H, Liefhold J. Hydromorphone: review of pharmacological properties and therapeutic efficacy with special regard to a controlled release preparation [in German]. Schmerz 1998; 12: 195-204
220. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003; 25: 169-78
221. Coursey CE. The psychomimetic side effects of pentazocine. Drug Intell Clin Pharm 1978; 12: 341-6
222. Li Wan Po A, Zhang WY. Systemic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997; 315: 1565-71
223. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention, and management. Drug Saf 1999; 21: 101-22
224. Weiner D, Hanlon JT, Studenski S. CNS drug-related fall liability in community-dwelling elderly. Gerontology 1998; 44: 217-21
225. Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, editors. Topics in palliative care. New York: Oxford University Press, 1997: 95-112
226. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1999; 5: 363-7
227. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. cardiac and analgesic drugs. J Am Geriatr Soc 1999; 47: 40-50
228. Egbert AM. Postoperative pain management in the frail elderly. Clin Geriatr Med 1996; 12: 583-99
229. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992; 47: 646-52
230. Leo RJ, Singh A. Pain management in the elderly: use of psychopharmacologic agents. Ann Long-Term Care 2002; 10 (2): 37-45
231. Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacologie properties and therapeutic use in chronic pain states. Drugs Aging 1996; 8 (6): 459-76
232. Lindsay PG, Olsen RB. Maprotiline in pain-depression. J Clin Psychiatry 1985 Jun; 46 (6): 226-8
233. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of the current literature. Harv Rev Psychiatry 2000; 7: 257-77
234. Loldrup D, Langemark M, Hansen HJ, et al. Clomipramine and mianserin in chronic idiopathic pain syndrome. Psychopharmacology 1989; 99 (1): 1-7
235. Yosselson-Superstine S, Lipman AG, Sanders SH. Adjunctive antianxiety agents in the management of chronic pain. Isr J Med Sci 1985; 21: 113-7
236. Baron R, Wasner G, Lindner V. Optimal treatment of phantom limb pain in the elderly. Drugs Aging 1998 May; 12 (5): 361-76
237. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997; 12 (6): 384-9
238. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1992 Nov; 52 (5): 547-52
239. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor citalopram relieves the syptoms of diabetic neuropathy. Pain 1990 Aug; 42 (2): 135-44
240. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized controlled trial. Neurology 2003 Apr 22; 60 (8): 1284-9
241. Chiu HF. Antidepressants in the elderly. Int J Clin Pract 1997; 51 (6): 369-74
242. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995 Oct 21; 311 (7012): 1047-52
243. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215-24
244. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomised controlled trial. JAMA 1998; 280: 1831-6
245. Zeyfang A, Nikolaus T. Activities of daily living (ADL) are more impaired among geriatric diabetic patients compared to non diabetic subjects [abstract]. Diabetologia 2002, 45 S1 A 304
246. Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611-4
247. Happe S, Klösch G, Saletu B, et al. Treatment of restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57: 1717-9
248. Bone M, Buggy D, Critchley R, et al. Gabapentin monotherapy in postamputation limb and stump pain: a randomized double-blind, placebo-controlled, cross-over study [abstract]. Eur J Anaesth 2001; 18: S2/A454
249. Schachter SC, Sauter MK. Treatment of central pain with gabapentin: case reports. J Epilepsy 1996; 9: 223-6
250. Backonja M, Glanzmann RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled trials. Clin Ther 2003 Jan; 25 (1): 81-104
251. Laughlin TM, Tram KV, Wilcox GL. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged and chronic nociception. J Pharmacol Exp Ther 2002 Sep; 302 (3): 1168-75
252. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathiy pain. Clin J Pain 2003 Jan-Feb; 19 (1): 59-68
253. Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging 2001; 18 (8): 561-73
254. Watson CP, Evans RJ, Watt VR. Post-herpetic neuralgia and topical capsaicin. Pain 1988; 33: 333-40
255. Peikert A, Henrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol 1991; 238 (8): 452-6
256. McQuay H, Moore A. An evidence based resource for pain relief: topical capsaicin. Oxford: Oxford University Press, 1998: 249-51
257. Watson CPN. Topical Capsaicin as an adjuvant analgesic. J Pain Symptom Manag 1994; 9: 425-33
258. Zhang WX, Li Wan Po A. The effectiveness of topically applied capsaicin: a metaanalysis. Eur J Clin Pharmacol 1999; 46: 517-22
259. Kastrup J, Bach FW, Petersen P, et al. Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma. Clin J Pain 1989; 5 (3): 239-44
260. Dejgard A, Petersen P, Castrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; I: 9-11
261. Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1995; 64: 283-91
262. Nikolajsen L, Gottrup H, Kristensen AGD, et al. Memantine (a N-Methyl-D-Aspartate Receptor Antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000; 91: 960-6
263. Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996; 67 (1): 69-77
264. Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002 May; 96 (5): 1053-61
265. Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med 2003 Feb; 20 (2): 114-8
266. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002 May; 30 (5 Suppl.): 67S-70S
267. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002 Nov; 13 (11): 858-67
268. Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 1998; 44: 2160-6
269. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48: 21-7
270. Martinez MJ, Roque M, Alonso-Coello P, et al. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2003; 3: CD003223
271. Hortobagyi GN, Theriault RL, Lester P, et al. Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91
272. Berenson JR, Lichtenstein A, Porter A, et al. Efficacy of pamidronate in reducing skeletal events in patients with multiple myeloma. N Engl J Med 1996; 334: 488-93
273. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med Jan 2000; 160 (10): 77-85
274. Freidman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7: 850-6
275. Altman RD, Hochberg MC, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905-15
276. Hollander JL. Intrasynovial corticosteroid therapy in arthritis. Md State Med J 1970; 19: 62-6
277. Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002; 23 (4): 346-50
278. Rumore MM, Schlichting DA. Clinical efficacy of antihistaminics as analgesics. Pain 1986; 25: 7-22
279. Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option for the management of pain? A qualitative systematic review. BMJ 2001; 323 (7303): 13-6